Research programme: neuropathic pain and spinal cord injury therapeutics - Algiax Pharmaceuticals

Drug Profile

Research programme: neuropathic pain and spinal cord injury therapeutics - Algiax Pharmaceuticals

Alternative Names: AP-19; AP-325; AP-61; AP-778

Latest Information Update: 08 Jan 2014

Price : $50

At a glance

  • Originator Algiax Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain; Spinal cord injuries

Most Recent Events

  • 31 Dec 2013 Preclinical trials in Neuropathic pain and Spinal cord injuries in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top